STOCKHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of business acquisitions, by acquisition

Stock issuances in relation to acquisitions during the years ended December 31, 2023, 2022 and 2021 were as follows:


(In thousands, except for per share data)	Period of Acquisition	Shares Issued	Fair Value of Shares Issued
OmicEra	May 2022	265,186	$	14,792
PreventionGenetics	December 2021	1,070,410	84,252
Ashion	April 2021	125,444	16,224
Thrive	January 2021	9,323,266	1,191,420
TARDIS license	January 2021	191,335	27,263

The acquisition date fair value of the consideration transferred for Resolution Bioscience was approximately $54.2 million, which consisted of the following:


(In thousands)
Cash	$	52,527
Fair value of replaced equity awards	1,675
Total purchase price	$	54,202

The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following:


(In thousands)
Common stock issued	$	14,792
Contingent consideration	4,600
Cash paid related to working capital adjustment	16
Total purchase price	$	19,408

The acquisition date fair value of the consideration transferred for PreventionGenetics was approximately $185.4 million, which consisted of the following:


(In thousands)
Cash	$	101,129
Common stock issued	84,252
Total purchase price	$	185,381

The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of the following:


(In thousands)
Cash	$	74,775
Common stock issued	16,224
Contingent consideration	19,000
Total purchase price	$	109,999

The acquisition date fair value of the consideration transferred for Thrive was approximately $2.19 billion, which consisted of the following:


(In thousands)
Common stock issued	$	1,175,431
Cash	584,996
Contingent consideration	331,348
Fair value of replaced equity awards	52,245
Previously held equity investment fair value	43,034
Total purchase price	$	2,187,054

Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI)

The amount recognized in AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:


(In thousands)	Cumulative Translation Adjustment		Unrealized Gain (Loss) on Securities (1)		AOCI
Balance at January 1, 2021	$	—	$	526	$	526
Other comprehensive income (loss) before reclassifications	23		(1,648)		(1,625)
Amounts reclassified from accumulated other comprehensive income (loss)	—		(514)		(514)
Net current period change in accumulated other comprehensive loss	23		(2,162)		(2,139)
Income tax benefit related to items of other comprehensive loss	—		170		170
Balance at December 31, 2021	$	23	$	(1,466)	$	(1,443)
Other comprehensive income (loss) before reclassifications	30		(4,049)		(4,019)
Amounts reclassified from accumulated other comprehensive income (loss)	—		226		226
Net current period change in accumulated other comprehensive loss	30		(3,823)		(3,793)
Balance at December 31, 2022	$	53	$	(5,289)	$	(5,236)
Other comprehensive income (loss) before reclassifications	1,321		1,416		2,737
Amounts reclassified from accumulated other comprehensive income (loss)	—		3,927		3,927
Net current period change in accumulated other comprehensive income (loss)	1,321		5,343		6,664
Balance at December 31, 2023	$	1,374	$	54	$	1,428

_________________________________

(1)There was no tax impact from the amounts recognized in AOCI for the years ended December 31, 2023 and 2022.

Schedule of amounts reclassified from accumulated other comprehensive income (loss)

Amounts reclassified from AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:


		Year Ended December 31,
Details about AOCI Components (In thousands)	Affected Line Item in the Statements of Operations	2023		2022		2021
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investments	Investment income (loss)	$	3,927	$	226	$	(514)
Total reclassifications		$	3,927	$	226	$	(514)